Celator Pharmaceuticals Corp.
Celator Pharmaceuticals Corp., a prominent player in the biopharmaceutical industry, is headquartered in California. Founded in 2000, the company has made significant strides in developing innovative cancer therapies, particularly through its proprietary technology, the CombiPlex® platform. This unique approach enhances the efficacy of existing treatments, setting Celator apart in a competitive market. With a focus on improving patient outcomes, Celator's core products include the FDA-approved Vyxeos™ (CPX-351), a novel chemotherapy formulation for acute myeloid leukaemia. The company has garnered recognition for its commitment to advancing cancer care, positioning itself as a leader in the oncology sector. Through strategic partnerships and a robust pipeline, Celator Pharmaceuticals continues to drive innovation and improve the lives of patients worldwide.
DitchCarbon Score
How does Celator Pharmaceuticals Corp.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Celator Pharmaceuticals Corp.'s score of 3 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Celator Pharmaceuticals Corp.'s reported carbon emissions
Celator Pharmaceuticals Corp., headquartered in California, currently does not have any publicly available carbon emissions data or specific climate commitments. As such, there are no reported figures regarding their carbon footprint, including Scope 1, 2, or 3 emissions. Additionally, the company has not outlined any reduction targets or initiatives related to climate action. In the absence of concrete data, it is unclear how Celator Pharmaceuticals is addressing climate change or contributing to sustainability efforts within the pharmaceutical industry.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Celator Pharmaceuticals Corp. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
